Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
The company has reported decrease of net loss for the whole year 2016, too. Net loss has decreased from € 20,5 million in 2015 to € 6,3 million in 2016.
The company said that clinical trials Concerto, Arpeggio and Legato-hd are progressing according to plan. The study results from the pivotal clinical Phase 3 Concerto trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017. The study results from the clinical Phase 2 Arpeggio trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
Orphan Drug Designation granted in the US by the FDA for laquinimod for the treatment of Huntington’s disease